Regorafenib Adverse Drug Reactions among Patients in King Abdullah Medical City; A Chart Review Study

Abstract

Regorafenib is widely known as an oral tyrosine kinase inhibitor and antineoplastic agent. It acts on various tyrosine kinase receptors, including oncogenic, stromal, and angiogenic receptors. This study was conducted to determine the safety profile of regorafenib in King Abdullah Medical City. All patients who had received regorafenib in King Abdullah Medical City between December 2021 and May 2020 were included in the study. The data collected included patient demographics, diagnosis, regorafenib starting and escalated doses, reported adverse events, and associated management. Forty-two patients were found to be on regorafenib. The average age of the patients was 56 years (ranging from 38 to 73 years) of which 12 were females and 30 were males. The majority of the patients received the drug for metastatic colon cancer. The most common adverse event reported in our study was hyperbilirubinemia followed by fatigue. This was in comparison to the adverse events reported in the published literature. spasm and bilateral hydronephrosis were found to be the new adverse drug reactions, which were not reported in other studies. Half of the patients were reported to have discontinued the medication due to adverse events. Regorafenib as evidenced by the published studies and findings of our study was found to be effective in the management of advanced cancers in our local population. However, it was found to be associated with a variety of adverse events comparable to the published studies.